Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02925104
Title A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Capmatinib

Age Groups: child | senior | adult
Covered Countries USA | ESP | DEU | AUT

Facility Status City State Zip Country Details
Indiana University Simon Cancer Center SC Indianapolis Indiana 46202 United States Details
Novartis Investigative Site Salzburg 5020 Austria Details
Novartis Investigative Site Herlev 2730 Denmark Details
Novartis Investigative Site Dresden 01307 Germany Details
Novartis Investigative Site Mainz 55131 Germany Details
Novartis Investigative Site Nijmegen 6500 HB Netherlands Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Santiago de Compostela Galicia 15706 Spain Details
Novartis Investigative Site Barcelona 08041 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Zaragoza 50009 Spain Details
Novartis Investigative Site Goteborg 413 45 Sweden Details
Novartis Investigative Site Lund SE-221 85 Sweden Details
Novartis Investigative Site Stockholm 171 76 Sweden Details
Novartis Investigative Site Uppsala SE-751 85 Sweden Details
Novartis Investigative Site London W1G 6AD United Kingdom Details
Novartis Investigative Site Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field